AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31881952 — intervention group
Group type: COMPARATOR
Intervention: Self-directed physical activity (DA), n=43.
Number of subjects: 144
Study 31881952 — intervention group
Group type: COMPARATOR
Intervention: Physically inactive (PI), n=48.
Number of subjects: 144
Study 28373244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary morphine (3 mg of morphine sulfate diluted with 3 mL of normal saline)
Number of subjects: 91
Study 28373244 — intervention group
Group type: COMPARATOR
Intervention: Control (3 mL of normal saline)
Number of subjects: 91
Study 28373244 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary morphine
Number of subjects: 91
Study 28373244 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 91
Study 27124841 — intervention group
Group type: EXPERIMENTAL
Intervention: CICADA method (ceasing CPAP with a view to remain off rather than slow weaning)
Number of subjects: 270
Study 27124841 — intervention group
Group type: EXPERIMENTAL
Intervention: CICADA method
Number of subjects: 270
Study 25149705 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 100 mg per day (Q100)
Number of subjects: 46
Study 25149705 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 300 mg per day (Q300)
Number of subjects: 46
Study 25149705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 21999406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined perianal-intrarectal lidocaine-prilocaine cream and lidocaine-ketorolac gel
Number of subjects: 200
Study 21999406 — intervention group
Group type: COMPARATOR
Intervention: Combined perianal-intrarectal lidocaine-prilocaine cream and periprostatic nerve block
Number of subjects: 200
Study 19084425 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemofiltration during cardiopulmonary bypass (CPB)
Number of subjects: 79
Study 19084425 — intervention group
Group type: COMPARATOR
Intervention: No haemofiltration during cardiopulmonary bypass (CPB)
Number of subjects: 79
Study 17884370 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide alone
Number of subjects: 159
Study 17884370 — intervention group
Group type: COMPARATOR
Intervention: Eptifibatide plus UFH
Number of subjects: 159
Study 15212194 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser needle acupuncture
Number of subjects: 29
Study 15212194 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 29
Study 15212194 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser needle acupuncture (females)
Number of subjects: 29
Study 12475427 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethcin rinse
Number of subjects: 19
Study 12475427 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 19
Study 9860085 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg b.i.d.
Number of subjects: 81
Study 9860085 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone (40 mg on day 1 decreased to 5 mg on day 7)
Number of subjects: 81
Study 7543605 — intervention group
Group type: EXPERIMENTAL
Intervention: Free PSA
Number of subjects: 422
Study 7543605 — intervention group
Group type: EXPERIMENTAL
Intervention: Complexed PSA
Number of subjects: 422
Study 7543605 — intervention group
Group type: EXPERIMENTAL
Intervention: Total PSA
Number of subjects: 422
Study 7543605 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-to-total PSA ratio
Number of subjects: 422
Study 7543605 — intervention group
Group type: EXPERIMENTAL
Intervention: Complexed-to-total PSA ratio
Number of subjects: 422
Study 7543605 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-to-complexed PSA ratio
Number of subjects: 422
Study 31331569 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage with topical 5 ml violet oil for 7 min during six sessions (two weeks)
Number of subjects: 57
Study 31331569 — intervention group
Group type: COMPARATOR
Intervention: Massage alone (without violet oil) for 7 min during six sessions (two weeks)
Number of subjects: 57
Study 28820681 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-induced heat therapy (RFHT) at 50°C for 30 seconds
Number of subjects: 213
Study 28820681 — intervention group
Group type: COMPARATOR
Intervention: Intralesional sodium stibogluconate (IL‐SSG) 1-3 mL given weekly until cure/10 doses
Number of subjects: 213
Study 26071690 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedicular PVP
Number of subjects: 50
Study 26071690 — intervention group
Group type: COMPARATOR
Intervention: Bipedicular PVP
Number of subjects: 50
Study 23167738 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealed-capsule irrigation (SCI) using distilled water (DW) for 3 minutes
Number of subjects: 60
Study 23167738 — intervention group
Group type: COMPARATOR
Intervention: Mechanical cleaning (MC) of the capsular bag
Number of subjects: 60
Study 20472172 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase (rt-PA)
Number of subjects: 3670
Study 20472172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3670
Study 17546453 — intervention group
Group type: EXPERIMENTAL
Intervention: AW group (additional water intake; n = 30)
Number of subjects: 60
Study 17546453 — intervention group
Group type: COMPARATOR
Intervention: NW group (no additional water intake; n = 30)
Number of subjects: 60
Study 17546453 — intervention group
Group type: EXPERIMENTAL
Intervention: AW group
Number of subjects: 60
Study 15734089 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ovarian drilling (LOD)
Number of subjects: 45
Study 12017404 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 48 microg via Turbuhaler
Number of subjects: 16
Study 12017404 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 800 microg via pMDI
Number of subjects: 16
Study 12017404 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 24 microg
Number of subjects: 16
Study 12017404 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 800 microg
Number of subjects: 16
Study 12017404 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 48 microg
Number of subjects: 16
Study 12017404 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol and Salbutamol
Number of subjects: 16
Study 10607970 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric morbidity (including 'subcases', 'organic' dementia, global depression, 'psychotic' depression, 'neurotic' depression, 'neuroses')
Number of subjects: 1080
Study 10607970 — intervention group
Group type: COMPARATOR
Intervention: Non-cases (reference group)
Number of subjects: 1080
Study 7574568 — intervention group
Group type: COMPARATOR
Intervention: Snack (not-hungry group)
Number of subjects: 157
Study 7574568 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-deprived (hungry group)
Number of subjects: 157
Study 2405556 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20-40 mg twice daily)
Number of subjects: 19
Study 2405556 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25-50 mg twice daily)
Number of subjects: 19
Study 2405556 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 19
Study 2405556 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 19
Study 6112526 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg three times a day for 2 weeks
Number of subjects: 37
Study 6112526 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 15 mg three times a day for 2 weeks
Number of subjects: 37
Study 6112526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 6112526 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (any dose)
Number of subjects: 37
Study 6112526 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (5 mg)
Number of subjects: 37
Study 30642370 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) for 24 weeks
Number of subjects: 0
Study 30642370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulation for 12 weeks)
Number of subjects: 0
Study 28819181 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting bronchoscopy when hypoventilation was detected (Study group)
Number of subjects: 114
Study 28819181 — intervention group
Group type: COMPARATOR
Intervention: Starting bronchoscopy when OAAS < 4 (Control group)
Number of subjects: 114
Study 26096521 — intervention group
Group type: EXPERIMENTAL
Intervention: Yellow Polylens Y30
Number of subjects: 32
Study 26096521 — intervention group
Group type: COMPARATOR
Intervention: Orange Series model PC 440Y
Number of subjects: 32
Study 26096521 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective visual impression
Number of subjects: 32
Study 24281271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment in dementia patients
Number of subjects: 272
Study 24281271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment in dementia patients with severe cognitive impairment
Number of subjects: 272
Study 24281271 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment in dementia patients with low to moderate cognitive impairment
Number of subjects: 272
Study 21681227 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable gastric stimulator (IGS) activated
Number of subjects: 13
Study 21681227 — intervention group
Group type: COMPARATOR
Intervention: Control group (IGS inactive)
Number of subjects: 13
Study 19073791 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (7 mg/d as multivitamin preparation with ferrous sulfate)
Number of subjects: 75
Study 19073791 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multivitamin preparation without iron)
Number of subjects: 75
Study 17697302 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-incision cholecystectomy (SIC)
Number of subjects: 257
Study 17697302 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 257
Study 17697302 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional open technique (conversion from SIC or LC)
Number of subjects: 257
Study 15729570 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoantibody-positive patients
Number of subjects: 4545
Study 15729570 — intervention group
Group type: COMPARATOR
Intervention: Autoantibody-negative patients
Number of subjects: 4545
Study 12414860 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 IU (2.5 mg) GH
Number of subjects: 7
Study 12414860 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 9472909 — intervention group
Group type: EXPERIMENTAL
Intervention: Black hypertensives with Stage 1-2 hypertension
Number of subjects: 0
Study 9472909 — intervention group
Group type: COMPARATOR
Intervention: White hypertensives with Stage 1-2 hypertension
Number of subjects: 0
Study 7629641 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. tubing directly connected to the infusion device
Number of subjects: 0
Study 7629641 — intervention group
Group type: COMPARATOR
Intervention: i.v. tubing connected to the latex port of an i.v. lock using a needle
Number of subjects: 0
Study 2520899 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplaque C
Number of subjects: 2
Study 2520899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 851246 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐chloroprocaine
Number of subjects: 200
Study 851246 — intervention group
Group type: EXPERIMENTAL
Intervention: bupivacaine
Number of subjects: 200
Study 30695650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ado-Trastuzumab Emtansine
Number of subjects: 0
Study 30365590 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% (w/w) hydrogen peroxide topical solution (HP40)
Number of subjects: 937
Study 30365590 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (VEH)
Number of subjects: 937
Study 27852282 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture that achieves the De‐qi sensation
Number of subjects: 60
Study 27852282 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture without needle insertion
Number of subjects: 60
Study 25307295 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (20 mg once daily)
Number of subjects: 2185
Study 25307295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study 22233728 — intervention group
Group type: EXPERIMENTAL
Intervention: Woman‐Focused intervention
Number of subjects: 100
Study 22233728 — intervention group
Group type: COMPARATOR
Intervention: Nutrition control
Number of subjects: 100
Study 19384841 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume-controlled ultrafiltration (BV-controlled UF)
Number of subjects: 26
Study 19384841 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodialysis (HD)
Number of subjects: 26
Study 17125466 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg)
Number of subjects: 12
Study 17125466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17125466 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg)
Number of subjects: 12
Study 17125466 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg) + L-NMMA
Number of subjects: 12
Study 17125466 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg) + L-NMMA + Fluconazole (0.37 mg.min(‐1).l(‐1))
Number of subjects: 12
Study 15766297 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol or penfluridol
Number of subjects: 215
Study 11865378 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted sigmoidectomy
Number of subjects: 42
Study 11865378 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 42
Study 10193727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with proteinuria
Number of subjects: 2784
Study 10193727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics without proteinuria
Number of subjects: 2784
Study 10193727 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetics
Number of subjects: 2784
Study 10193727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with low concentration proteinuria
Number of subjects: 2784
Study 10193727 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetics with high concentration proteinuria
Number of subjects: 2784
Study 7851007 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria peptide-diphtheria toxoid conjugates with aluminium hydroxide as an adjuvant
Number of subjects: 0
Study 7851007 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2162272 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute hypoglycaemia
Number of subjects: 0
Study 2162272 — intervention group
Group type: COMPARATOR
Intervention: Non-selective alpha-adrenergic blockade with phentolamine
Number of subjects: 0
Study 2162272 — intervention group
Group type: COMPARATOR
Intervention: Beta-adrenergic blockade with propranolol
Number of subjects: 0
Study 2162272 — intervention group
Group type: COMPARATOR
Intervention: Cholinergic blockade with atropine
Number of subjects: 0
Study 7462697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-recombinant influenza A virus (CR 22)
Number of subjects: 0
Study 29423956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarolaner
Number of subjects: 81
Study 29423956 — intervention group
Group type: COMPARATOR
Intervention: Moxidectin/imidacloprid
Number of subjects: 81
Study 28027367 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty hospitals for AMI
Number of subjects: 20351161
Study 28027367 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty hospitals for HF
Number of subjects: 20351161
Study 28027367 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty hospitals for pneumonia
Number of subjects: 20351161
Study 28027367 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty hospitals for nontarget conditions
Number of subjects: 20351161
Study 28027367 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty hospitals for AMI vs nontarget conditions
Number of subjects: 20351161
Study 28027367 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty hospitals for HF vs nontarget conditions
Number of subjects: 20351161
Study 28027367 — intervention group
Group type: EXPERIMENTAL
Intervention: Penalty hospitals for pneumonia vs nontarget conditions
Number of subjects: 20351161
Study 28027367 — intervention group
Group type: COMPARATOR
Intervention: Nonpenalty hospitals for AMI vs nontarget conditions
Number of subjects: 20351161
Study 28027367 — intervention group
Group type: COMPARATOR
Intervention: Nonpenalty hospitals for HF vs nontarget conditions
Number of subjects: 20351161
Study 28027367 — intervention group
Group type: COMPARATOR
Intervention: Nonpenalty hospitals for pneumonia vs nontarget conditions
Number of subjects: 20351161
Study 23660571 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) 300 mg·kg‐1 body mass
Number of subjects: 7
Study 23660571 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate (LACTATE) 1115 mg
Number of subjects: 7
Study 23660571 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (PL-BICARB) as placebo for NaHCO3
Number of subjects: 7
Study 23660571 — intervention group
Group type: COMPARATOR
Intervention: Plain flour (PL-LACTATE) as placebo for lactate
Number of subjects: 7
Study 22260629 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 204
Study 22260629 — intervention group
Group type: COMPARATOR
Intervention: Depression Relapse Active Monitoring (DRAM)
Number of subjects: 204
Study 20056803 — intervention group
Group type: EXPERIMENTAL
Intervention: Sergliflozin etabonate (5-500 mg)
Number of subjects: 30
Study 17188514 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-induced activation manipulation in Experiment 1
Number of subjects: 0
Study 17188514 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-induced activation manipulation in Experiment 2
Number of subjects: 0
Study 17188514 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime-induced activation manipulation in Experiment 3
Number of subjects: 0
Study 15934109 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed care settings (HMOs)
Number of subjects: 529
Study 12570928 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17-beta estradiol (ERT)
Number of subjects: 39
Study 12570928 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg 17-beta estradiol combined with continuous 5 mg medroxyprogesterone acetate (HRT)
Number of subjects: 39
Study 12570928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 10563646 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot training (MIT‐Manus) added to standard rehabilitation treatments
Number of subjects: 20
Study 10563646 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot training (MIT‐Manus)
Number of subjects: 20
Study 8754408 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelets from patients with chronic glomerulonephritis (CGN)
Number of subjects: 75
Study 8754408 — intervention group
Group type: COMPARATOR
Intervention: Platelets from healthy controls
Number of subjects: 75
Study 1702148 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB (cisplatin 120 mg/m2 day 3, vinblastine 12 mg/m2 day 1, bleomycin 15 U/m2 twice per week)
Number of subjects: 160
Study 1702148 — intervention group
Group type: COMPARATOR
Intervention: VPV (vinblastine 8 mg/m2 day 1, cisplatin 120 mg/m2 day 3, VP‐16 50 mg/m2 days 2 to 5)
Number of subjects: 160
Study 1702148 — intervention group
Group type: COMPARATOR
Intervention: VPV
Number of subjects: 160
Study 1702148 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB
Number of subjects: 160
Study 6342928 — intervention group
Group type: COMPARATOR
Intervention: 0.8% sodium monofluorophosphate (MFP)
Number of subjects: 1319
Study 6342928 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% sodium trimetaphosphate (TMP)
Number of subjects: 1319
Study 6342928 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.8% sodium monofluorophosphate)
Number of subjects: 1319
Study 31301135 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine-encoded adapted epitopes
Number of subjects: 2
Study 31301135 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HLA-I adaptation to the Gag vaccine insert
Number of subjects: 2
Study 31301135 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-I adaptation
Number of subjects: 2
Study 28756744 — intervention group
Group type: EXPERIMENTAL
Intervention: Real stimulation (tDCS)
Number of subjects: 10
Study 28756744 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study 26194728 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg (multiple doses)
Number of subjects: 26
Study 26194728 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 40 mg (single dose)
Number of subjects: 26
Study 26194728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 26
Study 26194728 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multiple doses)
Number of subjects: 26
Study 24452777 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated movements
Number of subjects: 0
Study 24452777 — intervention group
Group type: EXPERIMENTAL
Intervention: Human kinematic profile
Number of subjects: 0
Study 24452777 — intervention group
Group type: COMPARATOR
Intervention: Non-human kinematics (tempo-matched)
Number of subjects: 0
Study 23158943 — intervention group
Group type: EXPERIMENTAL
Intervention: CPM combined with Tuina treatment
Number of subjects: 66
Study 23158943 — intervention group
Group type: COMPARATOR
Intervention: Continuous passive training (CPM)
Number of subjects: 66
Study 21048484 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt (one cup, three times per day for 14 days)
Number of subjects: 81
Study 21048484 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 81
Study 21048484 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 81
Study 17621221 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP-2
Number of subjects: 148
Study 17621221 — intervention group
Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 148
Study 16308382 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal facilitated therapy with dolphins
Number of subjects: 30
Study 16308382 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 11964641 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL lidocaine (Group A, n=60)
Number of subjects: 120